Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, ...

Researchers found that burosumab safely corrected phosphate loss and improved mobility in patients with severe fibrous ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology ...

Expanded dosing options support individualized treatment for adults with XLH PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., tod ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving burosumab had a reduction in serum phosphate concentration z score at 1 year that was ...

A new international survey led by the International Osteoporosis Foundation reveals that adults living with hypophosphatemic osteomalacia (HO), a rare metabolic bone disorder, face a substantial and ...

A new international survey led by the International Osteoporosis Foundation reveals that adults living with hypophosphatemic osteomalacia (HO), a rare metabolic bone disorder, face a substantial and ...

A man in his early 60s became so progressively weak over 7 years that he could no longer walk -- and didn't realize he had fractured both femoral necks and 11 ribs. The cause: a tumor hiding in his ...

In this episode of The DrBicuspid.com Podcast, Editor-in-Chief Kevin Henry speaks with Dr. Juan Yepes, MPH, MS, DrPH, about X-linked hypophosphatemia (XLH), a genetic condition affecting phosphate ...

Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment ...